JNJ · NYSE
Johnson & Johnson
$263.81 -3.93 (-1.47%)
Company overview
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various healthcare products worldwide. In 2023, the company strategically separated its Consumer Health business into Kenvue Inc. to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands, including TYLENOL, LISTERINE, and BAND-AID, are now owned by Kenvue. The company's core focus is split between its Innovative Medicine segment (formerly Pharmaceutical), which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders, and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics, advanced surgery solutions, and disposable contact lenses under the ACUVUE brand.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Market cap
- $636B
- Employees
- 138,100
- Headquarters
- New Brunswick, NJ
- Website
- jnj.com
- CEO
- Joaquin Duato
- Listed
- January 2, 1943
- P/E
- 30.43
- Dividend yield
- 1.93%
Company financials
- Revenue
- $96.4B
- Gross profit
- $66.6B
- Operating income
- $25.9B
- EBITDA
- $31.6B
- Net income
- $21B
- EPS
- $8.67
- Total assets
- $201B
- Total debt
- $17.5B
- Gross margin
- 69.12%
- Net margin
- 21.83%
- Earnings yield
- 3.29%
Showing FY 2025
JNJ
1D
NYSE
O260.54H269.67L259.04C267.61+9.83 (+3.81%)Vol10.13M